期刊文献+

别嘌醇预处理对经皮冠状动脉介入治疗围手术期心肌损伤的影响

下载PDF
导出
摘要 目的探讨别嘌醇进行预处理对经皮冠状动脉介入治疗围手术期心肌损伤的影响。方法选取进行经皮冠状动脉介入治疗围手术期的患者共168例,随机分为研究组和对照组,每组84例。对照组患者在术前使用常规型药物治疗,研究组在对照组的治疗方案基础上再使用适量别嘌醇进行术前治疗,2组均在术后继续进行药物治疗,对照组仍使用常规治疗方案,研究组在对照组的基础上继续使用少量别嘌醇。记录所有患者的个体信息,同时在患者术后4~24 h内进行肌酸激酶同工酶(CK-MB)、肌钙蛋白(cTnT)、C-反应蛋白(CRP)、总胆固醇(TC)、低密度脂蛋白固醇(LDL-C)、高密度脂蛋白固醇(HDL-C)、三酰甘油(TG)等检测。对比2组患者上述术后检测指标的差异,将所有检测项目和记录信息代入逻辑斯特模型进行回归,记录回归结果。结果 2组患者的术后TC、LDL-C、HDL-C和TG指标差异无统计学意义(P>0.05),CK-MB、cTnT、CRP三项检测指标研究组均明显低于对照组(P<0.05)。别嘌呤预处理无法与患者的心肌损伤呈线性关系,但仍可以可以判断别嘌呤预处理能够有效的缓解患者出现心肌损伤的现象。结论别嘌醇预处理能够有效的缓解经皮冠状动脉介入治疗围期手术心肌损伤现象,提高患者愈后效果,降低患者病死率,值得在临床上推广。
出处 《河北医药》 CAS 2017年第1期63-65,共3页 Hebei Medical Journal
  • 相关文献

参考文献7

二级参考文献64

  • 1蹇祥玉.冠状动脉介入术中并发心室颤动的抢救护理[J].当代护士(中旬刊),2005,12(3):20-21. 被引量:1
  • 2王艳,成翼娟.局部应用苯妥英治疗各类创口效果的系统评价[J].中国循证医学杂志,2004,4(12):847-851. 被引量:15
  • 3Kushner FG, Hand M, Smith SC Jr, et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST Elevation Myocardial Infarction ( updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention ( updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 2009, 120: 2271-2300.
  • 4Grines CL, Bonow RO, Casey DE, et al. Prevention of premature discontinuation of dual anti platelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association. American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians, J Am Coli Cardiol,2007,49: 734-739.
  • 5Lanas A, Scheiman J. Low dose aspirin and upper gastrointestinal damage: epidemiology, preventionand treatment. Curr Med Res Opin, 2007, 23: 163 -177.
  • 6Yusuf S, Zhao F, Mehla SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST?segmentelevation. N Engl J Med,2001,345: 494-502.
  • 7Steg PG, Huber K, Andreotti F, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J,2011 ,32: 1854-1864.
  • 8Iakovou I, Schmidt T, Bonizzoni E,et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA,2005,293:2126-2130.
  • 9Yang X, Alexander KP, Chen AY.CRUSADE Investigators et al. The implications of blood transfusions for patients with non?ST -segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative, J Am Coli Cardiol, 2005,46:1490-1495.
  • 10Knudsen JB, Bastain W, Sefton CM, et al.Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics. Xenobiotica,1992,22: 579-589.

共引文献157

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部